Google
ACET — ADICET BIO INC (Healthcare >> Biotechnology)
ACET FAQ
What is ACET's ROE?
ADICET BIO INC reports a Return on Equity (ROE) of -77.70%.
What is ACET's dividend yield?
ADICET BIO INC offers a dividend yield of 0.00%.
What is ACET's Deepscope Quality Score?
Deepscope rates ACET's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ACET?
Deepscope's AI Timing Score for ACET is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ACET belong to?
ADICET BIO INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 7.31
Price
0.24
(3.28%)
Day Change
|
|
|---|
ACET, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 7.31 |
| PBV / Sector |
0.49 / 4.79
GREAT
|
| Earning Per Share | -11.64 |
| PE / Sector |
N/A / 17.89
|
| PEG or PE/Growth / Sector |
N/A / 0.56
|
| Average 1M Daily Value |
0.85 M
GREAT
|
| Average 1W Daily Value |
0.40 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-11 09:54:38 |
| Symbol | ACET |
| Name | ADICET BIO INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 9.35 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 68.34 / 8,963.32 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 131 Dartmouth Street, Boston, MA, United States, 02116
Phone: 650 503 9095
Website: https://www.adicetbio.com
Employees: 102
Sector: Healthcare >> Biotechnology
Description: Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
